For example , FDA approved drugs for the treatment of recurrent GBM, including small molecule inhibitors of the VEGFR kinase and anti-VEGF antibodies like bevacizumab, target the VEGF pathways (Table1). for additional therapeutic tools. We propose that targeting YKL-40 may enhance conventional anti-angiogenic therapies to provide a substantial clinical benefit to patients with GBM and several other types of solid tumors. Keywords: glioblastoma, YKL-40, glioblastoma stem-like cells, transdifferentiation, tumor angiogenesis == INTRO == Glioblastoma (GBM), a grade IV glioma, is the most lethal primary brain tumor in human being with a median survival of around 3 months without treatment and 12-15 months with therapeutic interventions [1-2]. Even with extensive surgical excision and Biotin-PEG3-amine post-operative attachment radio/chemotherapy, approximately half of patients relapse, and fewer than 3% of cancer patients survive longer than 5 years [34]. Although GBMs rarely propagate outside the central nervous system, they typically present because extensive infiltrating tumors with the ability to vigorously invade adjacent normal brain tissue, thereby precluding curative surgical removal. GBM is characterized by strong vascular proliferation that is associated with tumor cell growth, Biotin-PEG3-amine invasion, resistance to chemo/radiotherapy, and decreased disease-free survival [56]. Hence understanding the molecular mechanisms that mediate vascular development and pathogenesis is of paramount importance in clinical practice for patients who receive anti-angiogenic drug therapy. A number of distinct vascular phenotypes in GBM have been identified in which tumor angiogenesis is one of the most prominent forms of vascularization [78]. Tumor angiogenesis is a vessel-sprouting process characterized by the migration and proliferation of pre-existing vascular endothelial cells (ECs) followed by the recruitment of pericytes or smooth muscle cells (PC/SMCs) that support vessel stability and enable blood perfusion [9]. Some of the pre-existing vessels are also able to split and give rise to secondary daughter vessels, a vascular event known as intussusception [8]. Vessel co-option also occurs in Biotin-PEG3-amine some cases, whereby tumor cells drive or hijack pre-existing vessels in order to develop new vascular networks [1011]. Over the past a few years, an additional major form of tumor vascularization has been discovered in GBM in which tumor Rabbit Polyclonal to CPZ cells assemble to vascular channels, independent of endothelial cells [1213]. Such tumor cell-mediated vascular formation missing ECs is referred to as vasculogenic mimicry (VM) [14]. Over the past decade, the secreted glycoprotein YKL-40, also named chitinase 3-like 1 (Chi3l1) [1518], offers emerged as a potential mediator of GBM progression. YKL-40 is a highly conserved 40-kDa chitin- or heparin-binding glycoprotein, which places Biotin-PEG3-amine it into the family of chitinase-like proteins. However , YKL-40 lacks chitinase/hydrolase activity because of a mutation in the chitinase-3-like catalytic domain name that converts an essential glutamic acid into leucine residue. Gene expression profiling offers demonstrated that YKL-40 is ranked as one of the most dramatically induced genes in GBM [1920]. A wealth of clinical evidence has also revealed that elevated serum levels of YKL-40 in GBM are positively correlated with cancer invasiveness, radioresistance, recurrence, and reduced patient survival occasions [1925]. In concert with these findings, radiotherapy-resistant GBMs express elevated levels of YKL-40, which may at least partially contribute to the tumor malignancy [21, 26]. The roles and molecular mechanisms that mediate YKL-40-dependent vascularization of GBM have been the subject of several recent studies. We have found that YKL-40 acts as an angiogenic factor to promote tumor angiogenesis in both GBM and breast cancer [2728]. This review focuses primarily on the recently identified roles of YKL-40 in facilitating both angiogenesis and VM in GBM, with a focus on current therapeutic limitations evident in the treatment of patients with standard anti-angiogenic drugs. == 2 . TUMOR ANGIOGENESIS == == 2 . 1 . Endothelial cells == Tumor angiogenesis is a pathologic process that is primarily mediated by the growth and sprouting of vascular ECs [2930]. These ECs typically develop from vascular lineage differentiation of bone marrow-derived CD34+-hematopoietic stem cells. Other cell types can.